OBJECTIVE:Timolol maleate 0.5% gel is a safe and effective medication for treating superficial infantile hemangiomas (IHs) in infants with a median age of 9 weeks. METHODS:Forty-one infants who had superficial IHs without ulceration and not near mucosal surfaces were recruited and randomly assigned to placebo and treatment (timolol maleate 0.5% gel) groups. Efficacy was assessed by performing blinded volume measurements at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, and 24 and blinded investigator photograph scoring at weeks 0, 12, and 24. Safety was assessed by measuring heart rate and systolic and diastolic blood pressure at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, and 24. RESULTS:Fifteen of the 19 infants receiving treatment and 17 of the 22 infants receivingplacebo completed the study. Significant color change on the blinded photographic scores was noted at week 24 of the study (P = .003). There was a significantly higher proportion of treated IHs that reduced in size by >5% at weeks 20 and 24 (P < .02). The predicted proportion of IH volume change was also significantly less for treated IHs from week 16 onward when compared with placebo (P < .05). There was no significant variation in blood pressure and heart rate between the groups. CONCLUSIONS:Topical timolol maleate 0.5% gel with a maximum dose of 0.5 mg per day is a safe and effective option for small superficial IHs that have not ulcerated and are not on mucosal surfaces.
RCT Entities:
OBJECTIVE:Timolol maleate 0.5% gel is a safe and effective medication for treating superficial infantile hemangiomas (IHs) in infants with a median age of 9 weeks. METHODS: Forty-one infants who had superficial IHs without ulceration and not near mucosal surfaces were recruited and randomly assigned to placebo and treatment (timolol maleate 0.5% gel) groups. Efficacy was assessed by performing blinded volume measurements at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, and 24 and blinded investigator photograph scoring at weeks 0, 12, and 24. Safety was assessed by measuring heart rate and systolic and diastolic blood pressure at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20, and 24. RESULTS: Fifteen of the 19 infants receiving treatment and 17 of the 22 infants receiving placebo completed the study. Significant color change on the blinded photographic scores was noted at week 24 of the study (P = .003). There was a significantly higher proportion of treated IHs that reduced in size by >5% at weeks 20 and 24 (P < .02). The predicted proportion of IH volume change was also significantly less for treated IHs from week 16 onward when compared with placebo (P < .05). There was no significant variation in blood pressure and heart rate between the groups. CONCLUSIONS: Topical timolol maleate 0.5% gel with a maximum dose of 0.5 mg per day is a safe and effective option for small superficial IHs that have not ulcerated and are not on mucosal surfaces.
Authors: Anthony Cole Gallegos; Michael James Davis; Catherine N Tchanque-Fossuo; Kaitlyn West; Angela Eisentrout-Melton; Thomas R Peavy; Roy W Dixon; Roma P Patel; Sara Evona Dahle; Roslyn Rivkah Isseroff Journal: Adv Wound Care (New Rochelle) Date: 2019-10-16 Impact factor: 4.730
Authors: Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze Journal: Eur J Pediatr Date: 2015-05-29 Impact factor: 3.183
Authors: Shoná A Burkes; Manish Patel; Denise M Adams; Adrienne M Hammill; Kenneth P Eaton; R Randall Wickett; Marty O Visscher Journal: Int J Dermatol Date: 2016-04-08 Impact factor: 2.736